TGF Beta Receptor Type 1 - Pipeline Review, H1 2020
TGF Beta Receptor Type 1 - Pipeline Review, H1 2020
SUMMARY
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
The latest report TGF Beta Receptor Type 1 - Pipeline Review, H1 2020, outlays comprehensive information on the TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Transforming growth factor beta receptor I is a TGF beta receptor encoded by TGFBR1 gene. It is involved in physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Central Nervous System, Metabolic Disorders, Musculoskeletal Disorders and Toxicology which include indications Hepatocellular Carcinoma, Myelodysplastic Syndrome, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pulmonary Fibrosis, Sarcomas, Solid Tumor, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Androgenic Alopecia, Bladder Cancer, Bone Metastasis, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Degenerative Disc Disease, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Bowel Disease, Keloids, Liver Fibrosis, Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Oral Mucositis, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Prostate Cancer, Radiodermatitis, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wounds.
Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
The latest report TGF Beta Receptor Type 1 - Pipeline Review, H1 2020, outlays comprehensive information on the TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Transforming growth factor beta receptor I is a TGF beta receptor encoded by TGFBR1 gene. It is involved in physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Central Nervous System, Metabolic Disorders, Musculoskeletal Disorders and Toxicology which include indications Hepatocellular Carcinoma, Myelodysplastic Syndrome, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pulmonary Fibrosis, Sarcomas, Solid Tumor, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Androgenic Alopecia, Bladder Cancer, Bone Metastasis, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Degenerative Disc Disease, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Bowel Disease, Keloids, Liver Fibrosis, Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Oral Mucositis, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Prostate Cancer, Radiodermatitis, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wounds.
Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30)
- The report reviews TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects
- The report assesses TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Overview
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
Allander Biotechnologies LLC
Auxagen Inc
Eli Lilly and Co
FBM Therapeutics LLC
GenFleet Therapeutics
MedPacto Inc
Pfizer Inc
Shanghai Yingli Pharmaceutical Co Ltd
SK Chemicals Co Ltd
Synthis LLC
Taisho Pharmaceutical Holdings Co Ltd
TherapyX Inc
Theravance Biopharma Inc
TiumBio Co Ltd
Yuhan Corp
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Drug Profiles
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galunisertib monohydrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GFH-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Antagonize TGF-beta for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06952229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKI-2162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ALK5 for Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRI-011381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0427736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vactosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-14618 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YL-13027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZL-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Dormant Products
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Discontinued Products
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2019: MedPacto passes tech assessment, seeks KOSDAQ listing this year
May 15, 2019: Eli Lilly presents update on phase Ib study of galunisertib at ASCO 2019
Jan 23, 2019: Study Suggests new strategy to treat advanced Prostate Cancer
Dec 21, 2018: MedPacto announce approval for the Vactosertib + Durvalumab Combination Trial Application
Aug 31, 2017: Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol
May 18, 2016: Lilly to present data on TGF? small-molecule kinase inhibitor galunisertib at ASCO
May 14, 2013: Lilly Oncology To Release New Pipeline Data On TGF Beta Inhibitor LY2157299 At ASCO 2013
Apr 10, 2013: Lilly Presents Data On TGF-beta Inhibitor LY2157299 At AACR Annual Meeting
Jul 01, 2009: Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecule Activin-Like Kinase 5 Inhibitor (ALK-5) From Pfizer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Overview
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
Allander Biotechnologies LLC
Auxagen Inc
Eli Lilly and Co
FBM Therapeutics LLC
GenFleet Therapeutics
MedPacto Inc
Pfizer Inc
Shanghai Yingli Pharmaceutical Co Ltd
SK Chemicals Co Ltd
Synthis LLC
Taisho Pharmaceutical Holdings Co Ltd
TherapyX Inc
Theravance Biopharma Inc
TiumBio Co Ltd
Yuhan Corp
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Drug Profiles
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galunisertib monohydrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GFH-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Antagonize TGF-beta for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06952229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKI-2162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ALK5 for Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRI-011381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0427736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vactosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-14618 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YL-13027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZL-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Dormant Products
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Discontinued Products
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2019: MedPacto passes tech assessment, seeks KOSDAQ listing this year
May 15, 2019: Eli Lilly presents update on phase Ib study of galunisertib at ASCO 2019
Jan 23, 2019: Study Suggests new strategy to treat advanced Prostate Cancer
Dec 21, 2018: MedPacto announce approval for the Vactosertib + Durvalumab Combination Trial Application
Aug 31, 2017: Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol
May 18, 2016: Lilly to present data on TGF? small-molecule kinase inhibitor galunisertib at ASCO
May 14, 2013: Lilly Oncology To Release New Pipeline Data On TGF Beta Inhibitor LY2157299 At ASCO 2013
Apr 10, 2013: Lilly Presents Data On TGF-beta Inhibitor LY2157299 At AACR Annual Meeting
Jul 01, 2009: Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecule Activin-Like Kinase 5 Inhibitor (ALK-5) From Pfizer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Allander Biotechnologies LLC, H1 2020
Pipeline by Auxagen Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by FBM Therapeutics LLC, H1 2020
Pipeline by GenFleet Therapeutics, H1 2020
Pipeline by MedPacto Inc, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H1 2020
Pipeline by SK Chemicals Co Ltd, H1 2020
Pipeline by Synthis LLC, H1 2020
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2020
Pipeline by TherapyX Inc, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Pipeline by TiumBio Co Ltd, H1 2020
Pipeline by Yuhan Corp, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Allander Biotechnologies LLC, H1 2020
Pipeline by Auxagen Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by FBM Therapeutics LLC, H1 2020
Pipeline by GenFleet Therapeutics, H1 2020
Pipeline by MedPacto Inc, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H1 2020
Pipeline by SK Chemicals Co Ltd, H1 2020
Pipeline by Synthis LLC, H1 2020
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2020
Pipeline by TherapyX Inc, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Pipeline by TiumBio Co Ltd, H1 2020
Pipeline by Yuhan Corp, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Allander Biotechnologies LLC
Auxagen Inc
Eli Lilly and Co
FBM Therapeutics LLC
GenFleet Therapeutics
MedPacto Inc
Pfizer Inc
Shanghai Yingli Pharmaceutical Co Ltd
SK Chemicals Co Ltd
Synthis LLC
Taisho Pharmaceutical Holdings Co Ltd
TherapyX Inc
Theravance Biopharma Inc
TiumBio Co Ltd
Yuhan Corp
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Allander Biotechnologies LLC
Auxagen Inc
Eli Lilly and Co
FBM Therapeutics LLC
GenFleet Therapeutics
MedPacto Inc
Pfizer Inc
Shanghai Yingli Pharmaceutical Co Ltd
SK Chemicals Co Ltd
Synthis LLC
Taisho Pharmaceutical Holdings Co Ltd
TherapyX Inc
Theravance Biopharma Inc
TiumBio Co Ltd
Yuhan Corp
